Asco-GU 2020: revving up for Peloton deal validation

Last year Merck & Co paid over $1bn to buy Peloton Therapeutics on the back of data that, while very impressive, came from just 55 subjects. An update from this first-in-human study on Saturday should give a better idea whether this was money well spent.